The Food and Drug Administration is investigating serious adverse events involving Limbrel, a capsule being marketed as a medical food to manage the metabolic processes associated with osteoarthritis. Health care providers who know their patients are taking the product should advise them to stop taking it immediately, FDA said. While a range of adverse events have been reported, two serious and potentially life-threatening medical conditions are among them: drug-induced liver injury and hypersensitivity pneumonitis. For more information, see the FDA safety alert.

Related News Articles

Headline
The House Energy and Commerce Committee today approved legislation to address surprise medical bills and Medicaid disproportionate share hospital cuts.
Headline
Mary Beth Kingston spoke today at the first of three regional forums on the Future of Nursing 2020-2030.
Headline
The AHA today voiced support for legislation to revise and extend federal programs to develop the nursing workforce.
Perspective
There’s no question that hospitals and health systems face a number of challenges.
Headline
Reps. Bradley Schneider, D-Ill., Don Bacon, R-Neb., and Abby Finkenauer, D-Iowa, yesterday introduced a House companion to AHA-supported legislation that would…
Insights and Analysis
Also in this weekly roundup of nursing news: a nurse helps save the life of a man at the theatre, and executive moves in the field.